Long-term remission of adenoid cystic tongue carcinoma with low dose naltrexone and vitamin D3--a case report.

No abstract is available for this paper.

• Publication year

  2014

• Venue

  Oral Health and Dental Management

• Publication date

  2014-09-01

• Fields of study

  Medicine

• Identifiers
  PMID 25284545
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Adenoid Cystic Carcinoma: Clinical and Molecular Features

  2013cited by this paper
• Opioid antagonists for the treatment of alcohol dependence.

  2011cited by this paper
• Metabolic Modulation of Glioblastoma with Dichloroacetate

  2010cited by this paper
• Non-Hodgkin's Lymphoma Reversal with Dichloroacetate

  2010cited by this paper
• Opioid growth factor improves clinical benefit and survival in patients with advanced pancreatic cancer.

  2010cited by this paper
• Revisiting the ALA/N (α-Lipoic Acid/Low-Dose Naltrexone) Protocol for People With Metastatic and Nonmetastatic Pancreatic Cancer: A Report of 3 New Cases

  2009cited by this paper
• Growth inhibition of thyroid follicular cell-derived cancers by the opioid growth factor (OGF) - opioid growth factor receptor (OGFr) axis

  2009cited by this paper
• A phase II trial of tetrathiomolybdate after surgery for malignant mesothelioma: final results.

  2008cited by this paper
• A mitochondria-K+ channel axis is suppressed in cancer and its normalization promotes apoptosis and inhibits cancer growth.

  2007cited by this paper
• Reversal of Signs and Symptoms of a B-Cell Lymphoma in a Patient Using Only Low-Dose Naltrexone

  2007cited by this paper
• The Long-term Survival of a Patient With Pancreatic Cancer With Metastases to the Liver After Treatment With the Intravenous α-Lipoic Acid/Low-Dose Naltrexone Protocol

  2006cited by this paper
• Combination chemotherapy with gemcitabine and biotherapy with opioid growth factor (OGF) enhances the growth inhibition of pancreatic adenocarcinoma

  2005cited by this paper
• Opioid growth factor (OGF) inhibits anchorage-independent growth in human cancer cells.

  2004cited by this paper
• Treatment of advanced pancreatic cancer with opioid growth factor: phase I

  2004cited by this paper
• Opioid growth factor (OGF) inhibits the progression of human squamous cell carcinoma of the head and neck transplanted into nude mice.

  2003cited by this paper
• Phase II trial of tetrathiomolybdate in patients with advanced kidney cancer.

  2003cited by this paper
• The expression and function of the OGF-OGFr axis - a tonically active negative regulator of growth - in COS cells.

  2003cited by this paper
• Cancer Therapy With Tetrathiomolybdate: Antiangiogenesis by Lowering Body Copper—A Review

  2002cited by this paper
• Treatment of metastatic cancer with tetrathiomolybdate, an anticopper, antiangiogenic agent: Phase I study.

  2000cited by this paper
• Differentiation of neoplastic cells toward normal induced by vitamin D3 derivatives.

  1994cited by this paper
• Regulation of vitamin D receptor abundance and responsiveness during differentiation of HT-29 human colon cancer cells.

  1993cited by this paper
• Signaling pathways for vitamin D-induced differentiation: implications for therapy of proliferative and neoplastic diseases.

  1993cited by this paper
• Vitamin D: a modulator of cell proliferation and differentiation.

  1990cited by this paper
• Enhancement of natural cytotoxicity by beta-endorphin.

  1983cited by this paper

• Low-Dose Naltrexone as an Adjuvant in Combined Anticancer Therapy

  2024influential citation
• Naltrexone at low doses (LDN) and its relevance to cancer therapy

  2022cites this paper
• Possible Therapeutics for Pseudomyxoma Peritonei: A Rare, Lethal, and the Least Investigated Disease

  2022cites this paper
• Antagonists of the Mu-Opioid Receptor in the Cancer Patient: Fact or Fiction?

  2022cites this paper
• Preclinical and clinical studies into the bioactivity of low-dose naltrexone (LDN) for oncotherapy.

  2021cites this paper
• Low Doses Naltrexone: The Potential Benefit Effects for its Use in Patients with Cancer.

  2021cites this paper
• Research progress of opioid growth factor in immune-related diseases and cancer diseases.

  2021cites this paper
• Impact of Opioid Use in Hematological Malignancies: Clinical, Immunological and Concomitant Aspects

  2020cites this paper
• Naltrexone’s Impact on Cancer Progression and Mortality: A Systematic Review of Studies in Humans, Animal Models, and Cell Cultures

  2020cites this paper
• Interaction of opioid growth factor (OGF) and opioid antagonist and their significance in cancer therapy.

  2019cites this paper
• Prospective oncotarget for gynecological cancer: Opioid growth factor (OGF) - opioid growth factor receptor (OGFr) axis.

  2019cites this paper
• Low-Dose Naltrexone in Combination with High-Dose Vitamin C in Cancer Patients: Our Experience and Medical Literature Review - it should be Reinforced in Our Practices of Integrative Oncology

  2019cites this paper
• Molecular Medicine Letters Could Low-Dose Naltrexone be an Effective Treatment for Hailey-Hailey Disease?

  2018influential citation
• The Safety and Efficacy of Low‐Dose Naltrexone in the Management of Chronic Pain and Inflammation in Multiple Sclerosis, Fibromyalgia, Crohn's Disease, and Other Chronic Pain Disorders

  2018cites this paper
• Integrative Biomedical Sciences Could Low-Dose Naltrexone be an Effective Treatment for Hailey-Hailey Disease?

  2018influential citation
• Low-dose naltrexone (LDN): A promising treatment in immune-related diseases and cancer therapy.

  2018cites this paper
• Could low-dose naltrexone be an effective treatment for Hailey-Hailey Disease?

  2016cites this paper